PubReading [115] - Therapeutic application of sequence-specific binding molecules for novel genome editing tools - J. Nakao, T. Yamamoto and A. Yamayoshi

<p><strong>Genome editing</strong> has been expected to widely increase the available treatment options for various diseases and permit <strong>pharmaceutical interventions</strong> in previously untreatable conditions. The availability of genome editing tools was dramatically increased by the development of the <strong>CRISPR-Cas9</strong> system. However, a number of issues limit the use of the CRISPR-Cas9 system and other gene-editing tools in the clinical treatment of diseases. This review summarized the history and types of genome editing tools and limitations of their use. In addition, the study addressed several next-generation technologies aiming to overcome the limitations of current gene therapy protocols in an effort to accelerate the clinical development of potential treatment options. This review has provided an extensive foundation of the current state of genome editing technology and its <strong>clinical development</strong>. This review also indicate that the study additionally highlighted the need for multidisciplinary approaches to overcome current bottlenecks in the development of genome editing.</p><p><a href="https://doi.org/10.1016/j.dmpk.2021.100427"><em>https://doi.org/10.1016/j.dmpk.2021.100427</em></a><em> - 2022</em></p>